title: SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
abstract: Pituitary carcinomas are rare and neurosurgically challenging lesions, as they commonly relapse after surgical removal. Their prognosis is dismal due to their limited response to radiotherapy and chemotherapy. In recent studies, temozolomide was administered in very few patients with partial effects. We report a patient with an ACTH-secreting pituitary carcinoma and widespread intracranial, spinal and systemic metastases despite repeated surgical treatment, bilateral adrenalectomy, medical treatment and radiotherapy. Additionally to chemotherapy with temozolomide, the patient received SOM230 as salvage therapy with an improvement of the patient's clinical status, and a reduction of ACTH levels. After 12 months of combination therapy a sustained tumor control was achieved and persisted upon monotherapy with SOM230 for more than 9 months thereafter. Thus, temozolomide in combination with SOM230 seems to be promising in patients with ACTH-secreting metastasized pituitary carcinoma.
authors.affiliation: Medical Faculty Mannheim, V Medizinische Klinik, University Hospital Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer, Mannheim, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Bode
authors.forename: M
authors.initials: M
authors.lastname: Seiz
authors.forename: A
authors.initials: A
authors.lastname: Lammert
authors.forename: M A
authors.initials: MA
authors.lastname: Brockmann
authors.forename: W
authors.initials: W
authors.lastname: Back
authors.forename: H-P
authors.initials: HP
authors.lastname: Hammes
authors.forename: C
authors.initials: C
authors.lastname: Thomé
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000378:metabolism*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D016879:Salvage Therapy; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D013004:Somatostatin; D003606:Dacarbazine; D000324:Adrenocorticotropic Hormone; C517782:pasireotide; D000077204:Temozolomide